• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

xerispharmaceuticals

Xeris, Tetra Pharma enter $71M licensing agreement for glucagon injection

July 19, 2021 By Sean Whooley

Xeris Tetris Pharma

Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes […]

Filed Under: Business/Financial News, Contract Services, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Tetris Pharma, Xeris Pharmaceuticals, xerispharmaceuticals

Xeris Pharmaceuticals prices $27M offering

March 11, 2021 By Sean Whooley

Xeris Pharmaceuticals logo - updated

Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. The offering is priced at $4.12 per share, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals launches autoinjector for severe hypoglycemia

July 1, 2020 By Danielle Kirsh

gvoke-xeris

Xeris Pharmaceuticals today said it has launched its Gvoke HypoPen glucagon injection to treat severe hypoglycemia. The autoinjector is designed to treat severe hypoglycemia in adults and children with diabetes that are ages two years and older. The premixed autoinjector has no visible needle and has a reliable delivery method. According to the company, 99% […]

Filed Under: Auto-injectors, Diabetes Tagged With: xerispharmaceuticals

FDA approves ready-to-use liquid glucagon from Xeris

September 12, 2019 By Sean Whooley

Xeris Pharmaceuticals logo - updated

Xeris Pharmaceuticals (NSDQ:XERS) said yesterday that the FDA has approved its Gvoke glucagon injection for the treatment of hypoglycemia. Gvoke is a ready-to-use, room-temperature, stable liquid glucagon designed to treat severe hypoglycemia in pediatric and adult patients with Type 1 diabetes aged two years old or above. Chicago-based Xeris’ Gvoke may be administered with a pre-filled […]

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: FDA, Juvenile Diabetes Research Foundation (JDRF), xerispharmaceuticals

Xeris launches Ph2 trial of ready-to-use liquid glucagon

March 15, 2019 By Sarah Faulkner

Xeris Pharmaceuticals logo - updated

Xeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes. The Chicago-based company expects to report top-line data from the study in the second half of 2019. The trial is slated to assess Xeris’ room-temperature stable liquid glucagon as […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals touts data for glucagon auto-injector

November 14, 2018 By Sarah Faulkner

Xeris Pharmaceuticals logo - updated

Xeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability. The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes. “Hypoglycemia can quickly evolve from a mild event to an emergency, so prompt and reliable intervention […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: xerispharmaceuticals

FDA to review Xeris’ glucagon rescue pen auto-injector

October 24, 2018 By Sarah Faulkner

Xeris Pharmaceuticals logo - updated

Xeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device. The company’s product is designed to treat severe hypoglycemia in people with diabetes. The FDA is slated to make a decision about Xeris’ pen by June 10, 2019. “The FDA acceptance of our NDA for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: xerispharmaceuticals

Xeris Pharmaceuticals kicks off dual-hormone artificial pancreas trial

August 20, 2018 By Sarah Faulkner

Xeris Pharmaceuticals

Xeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system. Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: xerispharmaceuticals

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS